In EMJ GOLD’s latest Catalyst interview, AstraZeneca’s Dr Vikram Chand talks to Dr Julie-Ann Lough about his personal connection to triple negative breast cancer, how to tackle long standing inequities in oncology and the promise he sees in next generation ADCs
Speaker bios
Dr Vikram Chand
Dr Vikram Chand, Vice President, Global Franchise Head, AstraZeneca, brings over 15 years of experience in the biopharmaceutical industry, having worked across every stage of a medicine’s development, from early research to late phase trials and global registration. In his current role, he leads the clinical strategy for one of AstraZeneca’s antibody drug conjugate assets across multiple solid tumours, drawing on his background as a trained medical oncologist and haematologist to bridge scientific innovation with real world patient needs.
Beyond his day to day, though, he is guided by the belief that no patient population is too small and no cancer too difficult to treat. As a leader, his passion lies in defining a clear, patient centric vision, mapping an efficient path to achieve it and enabling his teams to make that vision a reality while continually advocating for better outcomes and broader clinical trial access.
Dr Julie-Ann Lough
Julie Ann is an award-winning broadcaster and producer based in the UK. Following completion of her PhD in Chemistry and a career in forensic science, she moved to media production working extensively in science and health broadcasting. She has produced content for both the BBC and commercial channels in the UK on both radio and television. She has designed various novel experiments, including large human intervention studies for TV in conjunction with expert scientists, some of which have been published in peer-review journals, and thoroughly enjoys finding creative ways to explain complex scientific concepts to the general public. Dr Lough is a passionate science communicator with a keen interest in public health.
